Bagsværd, Denmark, 26 March 2015 - Novo Nordisk today announced that the company has decided to submit the prespecified interim analysis of DEVOTE as part of a Class II Resubmission of the New Drug Applications (NDAs) of Tresiba® and Ryzodeg® to the US Food and Drug Administration (FDA). The resubmission is expected to take place within the next month.
For further information
Media: | ||
Mette Kruse Danielsen | +45 3079 3883 | mkd@novonordisk.com (mailto:mkd@novonordisk.com) |
Ken Inchausti (US) | +1 609 514 8316 | kiau@novonordisk.com (mailto:kiau@novonordisk.com) |
Investors: | ||
Kasper Roseeuw Poulsen | +45 3079 4303 | krop@novonordisk.com (mailto:krop@novonordisk.com) |
Melanie Raouzeos | +45 3075 3479 | mrz@novonordisk.com (mailto:mrz@novonordisk.com) |
Daniel Bohsen | +45 3079 6376 | dabo@novonordisk.com (mailto:dabo@novonordisk.com) |
Frank Daniel Mersebach (US) | +1 609 235 8567 | fdni@novonordisk.com (mailto:fdni@novonordisk.com) |
Company Announcement No 23 / 2015
Company Announcement No 23 2015 (http://hugin.info/2013/R/1906649/678864.pdf)
This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Novo Nordisk A/S via Globenewswire
HUG#1906649